Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Julia J Wattacheril, MD, MPH Non-invasive biomarkers for metabolic dysfunction-associated steatosis liver disease (MASLD) are used to stratify risk and assess disease severity in our patients. In this episode, Dr. Peter Buch is joined by Dr. Julia Wattacheril, Associate Professor of Medicine at Columbia University Irving Medical Center, to discuss the American Gastroenterological Association’s clinical practice update on the role of noninvasive biomarkers in MASLD.